Boston Scientific (BSX) Announces C Losing of $210 EndoChoice (GI) Acquisition

November 22, 2016 8:39 AM EST
Get Alerts BSX Hot Sheet
Trade BSX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Boston Scientific Corporation (NYSE: BSX) announced the close of its acquisition of EndoChoice Holdings, Inc. (NYSE: GI). With the completion of the acquisition, EndoChoice will become part of the Boston Scientific Endoscopy business. EndoChoice is an Alpharetta, Georgia based company focused on the development and commercialization of infection control products, pathology services and single-use devices for specialists treating a wide range of gastrointestinal (GI) conditions.

The two organizations announced a definitive agreement on September 27, 2016 for Boston Scientific to acquire the EndoChoice business at a cash price of $8.00 per share for an approximate total of $210 million.

"We are excited to provide physicians more comprehensive solutions to help assess, diagnose and treat patients with GI conditions," said Art Butcher, senior vice president and president, Endoscopy, Boston Scientific. "Boston Scientific is a leader in the field of endoscopy and we are committed to providing innovative products and services to meet the changing and growing needs within the field."

The expanded portfolio will deliver a comprehensive array of GI services and devices for physicians in group practice settings as well as hospitals and ambulatory surgery centers. The combined business will reach growing areas within the GI continuum of care, including infection control and pathology lab services. Boston Scientific continues to evaluate strategic options for the Full Spectrum Endoscopy (FUSEĀ®) colonoscope, and anticipates providing an update on its plans for the platform by the end of the year.

The acquisition is expected to be breakeven to Boston Scientific adjusted earnings per share in 2017, and accretive thereafter. The transaction is expected to be less accretive (or dilutive, as the case may be) on a GAAP basis, due to amortization expense and transaction and integration costs. EndoChoice generated approximately $75 million of total sales in the twelve-month period ended September 30, 2016.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Guidance, Mergers and Acquisitions

Related Entities

Twitter, Earnings, Definitive Agreement

Add Your Comment